Ticker brief
AMLX AMYLYX PHARMACEUTICALS INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$34.74
1 day
-6.6%
14 days
+60.6%
mkt cap
·
signals 14d
105
authors 14d
52
crowd 14d
-0.5σ
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now -0.08 (−1 bearish … +1 bullish)
Who spoke52
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @zohmbastic | C | -1.38 | 9 | +0.27 |
| @AlertsAndNews | C | -1.90 | 6 | +0.27 |
| @SuperDuperInvst | C | -0.99 | 6 | -0.77 |
| @Quantumup1 | C | · | 5 | +0.44 |
| @PersimmonTI | A | -0.57 | 5 | +0.25 |
| @BiopharmIQ | B | · | 5 | +0.29 |
| @semodough | C | -3.01 | 4 | +0.31 |
| @OzmosiHealth | C | · | 3 | +0.22 |
| @PrismMarketView | C | · | 3 | +0.55 |
| @bioinvestor24 | A | -0.45 | 3 | -0.40 |
| @Brad_E_Schulz | C | · | 3 | +0.63 |
| @BPharmCatalyst | C | · | 2 | +0.32 |
| @Pharmdca | C | +0.82 | 2 | -0.10 |
| @fwpharma | B | +0.98 | 2 | +0.08 |
| @Briefingcom | B | +0.50 | 2 | +0.25 |
| @Greatstockpix | C | -0.89 | 2 | +0.00 |
| @OpenOutcrier | C | · | 2 | +0.45 |
| @fundmyfund | B | -1.58 | 2 | +0.55 |
| @PrismDM | A | -2.10 | 2 | +0.60 |
| @BabaNeal007 | C | -0.08 | 2 | +0.40 |
| @TalkMarkets | C | · | 2 | -0.50 |
| @FintwitAi | C | +1.14 | 2 | +0.67 |
| @XpertPATrader | C | -0.02 | 2 | +0.50 |
| @adamfeuerstein | A | +1.41 | 1 | +0.50 |
| @wallstengine | B | -1.90 | 1 | +0.65 |
Recent signals30of 105 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @SuperDuperInvst | -0.80 | Calls for AMLX below $35.50 today as a short thesis. — Reiterates a bearish short call with a near-term price level. | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.65 | AMLX raised over $500M following positive Phase 3 avexitide data. | — | tweet ↗ |
| 2026-08-27 | @bioinvestor24 | -0.25 | Questions extreme therapy pricing while comparing costs and revenue burdens across several drug makers. | -6.6% | tweet ↗ |
| 2026-08-27 | @Quantumup1 | +0.40 | Guggenheim raised AMLX's price target to $57 from $55 on improved probability of success. | -6.6% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | -0.35 | Contrasts VKTX's much larger market with skepticism toward AMLX's expensive peptide | -8.9% | tweet ↗ |
| 2026-08-24 | @semodough | +0.55 | Praises AMLX data and argues VKTX addresses a market roughly ten times larger. | -8.9% | tweet ↗ |
| 2026-08-23 | @AlertsAndNews | +0.55 | Highlights last week's winning names and expresses interest in repeating the performance. | -10.1% | tweet ↗ |
| 2026-08-22 | @NickDrendel | +0.20 | Screens liquid stocks at 52-week highs that doubled over the past year, sorted by volume. | -10.1% | tweet ↗ |
| 2026-08-21 | @equitydd | +0.30 | Lists leading stocks with the strongest weekly momentum; output is capped at six tickers. | -10.1% | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | +0.60 | Summarizes the week's largest biotech movers and their associated catalysts. | -10.1% | tweet ↗ |
| 2026-08-21 | @AlertsAndNews | +0.25 | Promotional weekly recap names prior successful plays without forward trade details. | -10.1% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | -0.95 | Start the first AMLX short tranche above $41.25 with a $42.55 stop. — Explicit short entry and stop are backed by an overvaluation and commercialization thesis. | -10.1% | tweet ↗ |
| 2026-08-20 | @SuperDuperInvst | -0.85 | Calls AMLX very overvalued and predicts heavy eventual selling after the rally. | -12.4% | tweet ↗ |
| 2026-08-20 | @FintwitAi | +0.65 | Highlights AMLX's 87% gain since a prior mention and another 3.7% daily rise. | -12.4% | tweet ↗ |
| 2026-08-20 | @XpertPATrader | +0.45 | Discloses a mixed book with tech/index shorts and crypto longs; limited to six named positions. | -12.4% | tweet ↗ |
| 2026-08-20 | @MartyChargin | +0.65 | Calls AMLX's move impressive despite a weak market. | -12.4% | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | -0.25 | Biotech opening roundup lists FDA, clinical-data, approval and offering catalysts with associated price moves. | -12.4% | tweet ↗ |
| 2026-08-20 | @fwpharma | -0.25 | Amylyx plans a $500M share sale while preparing a GLP-1 antagonist launch. | -12.4% | tweet ↗ |
| 2026-08-19 | @SuperDuperInvst | -0.55 | Reports covering an AMLX short for gains while retaining a bearish outlook. | -10.0% | tweet ↗ |
| 2026-08-19 | @BiopharmIQ | -0.15 | Lists opening biotech movers and their associated trial, offering, facility and collaboration catalysts | -10.0% | tweet ↗ |
| 2026-08-19 | @XpertPATrader | +0.55 | Recaps profitable long and short positions from an already successful trading day. | -10.0% | tweet ↗ |
| 2026-08-19 | @PersimmonTI | +0.25 | Explicitly states no AMLX position while expressing support for AMLX and legitimate biotech. | -10.0% | tweet ↗ |
| 2026-08-19 | @Quantumup1 | +0.60 | Stifel and Guggenheim raised Amylyx targets while reiterating bullish ratings. | -10.0% | tweet ↗ |
| 2026-08-19 | @fundmyfund | +0.40 | Highlights these names among the best weekly performers. | -10.0% | tweet ↗ |
| 2026-08-19 | @WallStDiaries | +0.60 | Reports a biotech rally led by AMLX's 63% phase-3-driven surge and multiple 52-week highs. | -10.0% | tweet ↗ |
| 2026-08-18 | @kunal00 | +0.00 | Educational chart review and next-day watchlist without specific entry intent. | -1.1% | tweet ↗ |
| 2026-08-18 | @PersimmonTI | +0.90 | Expresses emphatic optimism about Avexitide after highly significant clinical remarks. | -1.1% | tweet ↗ |
| 2026-08-18 | @AlertsAndNews | +0.50 | Highlights prior momentum winners and completed activity from the week. | -1.1% | tweet ↗ |
| 2026-08-18 | @PersimmonTI | -0.25 | Welcomes positive Avexitide data but questions AMLX valuation, offering risk, and market opportunity. | -1.1% | tweet ↗ |
| 2026-08-18 | @SuperDuperInvst | -0.55 | Reports AMLX proposing a $350 million public common-stock offering after a price spike. | -1.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.